Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVDL vs HCM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

AVDL Overall Winner 6-Pillar Tally: AVDL 4 – 1 HCM (1 Tie) Matrix Metrics: AVDL 7 – 3 HCM

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over HUTCHMED (China) Limited (HCM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas HCM carries 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs HCM
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
HCM NASDAQ
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
$13.22
-1.71% 1D
Market Cap $2.3B
TTM Revenue $549M
Forward P/E N/M
Beta / 30D Vol 0.64β · 45% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 31.0 Fund 44.0 Flow 50.0 Mom 56.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $14.15 · SMA50: $14.11

6-Pillar Scorecard Institutional Category Breakdown (AVDL 4 – 1 HCM)

Columns: Metric · AVDL · HCM
1. Valuation Multiples AVDL
Forward P/E 28.8x N/M
Trailing P/E 16.8x 134.0x
PEG Ratio 0.07x N/M
EV / Revenue 8.5x 4.2x
2. Growth & Scale AVDL
Revenue Growth (YoY) +54.9% +0.2%
Earnings Growth (YoY) +0.0% -96.5%
TTM Revenue (USD) $249M $549M
Market Cap $2.1B $2.3B
3. Profitability & Quality AVDL
Gross Margin 94.9% 13.3%
Operating Margin 2.5% -6.3%
Net Profit Margin -0.1% 3.3%
Return on Equity (ROE) -0.3% 1.5%
4. Balance Sheet & Cash Flow AVDL
Cash Generation (TTM) $2.7M EBITDA -$21M EBITDA
Cash Flow Margin 1.1% EBITDA Mgn -3.7% EBITDA Mgn
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE $7.25 Book/Sh · 1.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 2.4% (<1st %ile) 82.7% (73rd %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat HCM
OpEx & R&D Intensity N/A 19.6% of Rev ($108M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (7) vs HCM (3)
Institutional Metric AVDL HCM Criterion Row Edge
Market Capitalization
Scale
$2.1B $2.3B Larger Scale HCM
Trailing P/E Ratio
Valuation
16.8x 134.0x Lower Multiple AVDL
Forward P/E Ratio
Valuation
28.8x N/M Lower Multiple AVDL
Revenue Growth (YoY)
Growth
+54.9% +0.2% Higher Growth AVDL
Operating Margin (TTM)
Profitability
2.5% -6.3% Higher Margin AVDL
Net Profit Margin
Profitability
-0.1% 3.3% Higher Margin HCM
Return on Equity (ROE)
Capital Efficiency
-0.3% 1.5% Higher ROE HCM
52-Week Range Position
Momentum
89% ($6–$24) 53% ($10–$16) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 0.64β · 45% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 38.1 / 100 (SELL) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $549M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% 13.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev N/M PEG · 4.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) -$21M EBITDA ($7.25 Book/Sh · 1.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HCM +0.56 pp
AVDL: +0.65% · HCM: +1.21%
3M Horizon HCM +8.74 pp
AVDL: -5.67% · HCM: +3.07%
6M Horizon HCM +8.74 pp
AVDL: -5.67% · HCM: +3.07%
1Y Horizon HCM +8.74 pp
AVDL: -5.67% · HCM: +3.07%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs HCM. Trailing 12-month operating profitability (AVDL 2.5% vs HCM -6.3%) and valuation multiples (AVDL 28.8x vs HCM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
HCM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$549M
Gross Margin13.3%
Op. Margin-6.3%
ROE / Fwd P/E1.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HCM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 82.7%
IV Percentile 73rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HCM Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.3B market capitalization and -6.3% operating margin.
OpEx & R&D Reinvestment 19.6% of Rev ($108M)
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs HCM Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) is the stronger overall head-to-head candidate over HUTCHMED (China) Limited (HCM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AVDL carries a Unified Composite Score of 62.9/100 (BUY) at $21.64 (28.8x Forward P/E, 2.5% operating margin), whereas HCM carries 38.1/100 (SELL) at $13.22 (N/M Forward P/E, -6.3% operating margin). Technically, AVDL sits in a Markup phase (RSI 62.3, UNCLASSIFIED options structure) and HCM sits in a Neutral phase (RSI 38.5, UNCLASSIFIED options structure).

AVDL leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with HCM at +0.2% YoY revenue growth and -96.5% YoY earnings growth on $549M TTM revenue (13.3% gross margin, -6.3% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $549M for HCM. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 19.6% of Rev ($108M) (0 disclosures) for HCM.

AVDL screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas HCM trades at N/M Forward P/E, 134.0x Trailing P/E, N/M PEG, and 4.2x EV/Revenue (-3.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus HCM (1.5% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, HCM carries 82.7% implied volatility (73rd %ile, Elevated (60th–80th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.64β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.